{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen X"],"funding":["NHLBI NIH HHS","Australian Research Council"],"pagination":["689-700"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7925372"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(3)"],"pubmed_abstract":["<h4>Background</h4>Vitamin K antagonists (VKAs), such as warfarin, have remained the cornerstone of oral anticoagulation therapy in the prevention and treatment of thromboembolism for more than half a century. They function by impairing the biosynthesis of vitamin K-dependent (VKD) clotting factors through the inhibition of vitamin K epoxide reductase (VKOR). The challenge of VKAs therapy is their narrow therapeutic index and highly variable dosing requirements, which are partially the result of genetic variations of VKOR.<h4>Objectives</h4>The goal of this study was to search for an improved VKA that is tolerant to the genetic variations of its target enzyme.<h4>Methods</h4>A series of vitamin K derivatives with benzyl and related side-chain substitutions at the 3-position of 1,4-naphthoq"],"journal":["Journal of thrombosis and haemostasis : JTH"],"pubmed_title":["A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase."],"pmcid":["PMC7925372"],"funding_grant_id":["R01 HL131690","FT110100851"],"pubmed_authors":["Liu Y","Paul Savage G","Williams CM","Jin DY","Chen X","Tie JK","Suhara Y","Furukawa N","Stafford DW"],"additional_accession":[]},"is_claimable":false,"name":"A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase.","description":"<h4>Background</h4>Vitamin K antagonists (VKAs), such as warfarin, have remained the cornerstone of oral anticoagulation therapy in the prevention and treatment of thromboembolism for more than half a century. They function by impairing the biosynthesis of vitamin K-dependent (VKD) clotting factors through the inhibition of vitamin K epoxide reductase (VKOR). The challenge of VKAs therapy is their narrow therapeutic index and highly variable dosing requirements, which are partially the result of genetic variations of VKOR.<h4>Objectives</h4>The goal of this study was to search for an improved VKA that is tolerant to the genetic variations of its target enzyme.<h4>Methods</h4>A series of vitamin K derivatives with benzyl and related side-chain substitutions at the 3-position of 1,4-naphthoq","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T19:54:16.55Z","creation":"2025-04-04T19:54:16.55Z"},"accession":"S-EPMC7925372","cross_references":{"pubmed":["33314621"],"doi":["10.1111/jth.15209"]}}